Endovascular stenting is accepted as an effective treatment for patients with Budd-Chiari syndrome (BCS). We herein present a case of successful endovascular treatment. A 46-year-old woman, who was followed up for 10 years after a diagnosis of BCS, showed progression progressive of liver cirrhosis and deterioration deteriorated of liver function. Three main hepatic veins were thrombosed with complete occlusion of the suprahepatic of the inferior vena cava (IVC); thus, hepatic venous blood flow was draining into the inferior right hepatic veins through the intrahepatic collaterals and passed passing through the subcutaneous venous collaterals. She underwent endovascular stenting of the IVC for palliation. A septoplasty needle was passed through the occluded IVC through into the internal jugular vein access and then to access the femoral vein using a snare wire. Severe elastic recoiling was observed after balloon dilatation; thus, a 28x80 mm stenting was done inserted across the occlusion, and repeat double ballooning was performed. The final venogram shows showed restored IVC inflow. The patient began to lose body weight 1 day after stenting, and edema disappeared within 1 week. She is was doing well at the 6 month follow-up visit with nearly normal liver function and marked resolution of cutaneous venous engorgement. In conclusion, endovascular stenting appeared to be an effective treatment to alleviate portal pressure and to prevent BCS-associated complications; thus, endovascular stenting should be considered before marked hepatic vein stenosis or complete occlusion occurs in patients with BCS. 
including ascites, hepatomegaly, splenomegaly, and progressive liver dysfunction. 3 As most of the significant symptoms and signs in patients with BCS are associated with portal hypertension, treatment is usually intended to relieve portal hypertension.
The anatomy of the hepatic veins is complex and distorted during progression of BCS; thus, it is not practical to surgically reconstruct the veins. Portal diversion treatment, such as side-to-side portocaval, mesocaval, and mesoatrial shunts, have been used, but these surgical methods are also associated with many serious complications.
Along with advances in radiological intervention technology, endovascular treatment has become a reliable treatment option for patients with symptomatic BCS.
Recanalization of occluded major hepatic veins or the 
CASE
A 46-year-old woman was followed up for 10 years after a BCS diagnosis ( Fig. 1 ). She was referred to us for LT due to progressive liver cirrhosis and deteriorated liver function. As a liver donor was unavailable, the patient underwent endovascular stenting of the IVC for palliation.
An abdominal computed tomography (CT) scan showed hepatomegaly and ascites, and gastrointestinal endoscopy revealed esophageal varices. Three main hepatic veins were thrombosed with complete occlusion of the suprahepatic IVC; thus, hepatic venous blood flow was draining into the inferior right hepatic vein through the intrahepatic collaterals and passing through the subcutaneous venous collaterals (Fig. 2A) . She was placed on the LT waiting list due to progressive liver cirrhosis and deteriorating liver function, but there was little possibility of deceased organ allocation considering the preserved status of liver function, and no living donor was available.
She underwent endovascular stenting of the IVC for palliation, rather than LT. A septoplasty needle was passed through the occluded IVC into the internal jugular vein and femoral vein using a snare wire. Severe elastic recoil (＞90%) was observed after balloon dilatation; thus, a 28×80-mm stent was inserted across the occluded area, and repeat double ballooning was performed. The final venogram shows restored IVC inflow (Fig. 3) .
She began to lose body weight 1 day after stenting, and the edema disappeared within the first week. A follow-up CT scan showed that the stented IVC was fully patent (Fig. 2B ) with complete thrombosis of the three main hepatic veins (Fig. 4A ), but intrahepatic collateral flow was draining through the right inferior hepatic vein with spontaneous closure of subcutaneous collateral veins (Fig. 4B ).
Liver function recovered slowly over several weeks.
Anticoagulation (warfarin) and anti-platelet therapy (aspirin) was started 4 days after stenting to minimize the risk of thrombotic occlusion of the IVC stent. She was doing well at the 6-month follow-up visit, with nearly normal liver function (total bilirubin, 0.9 mg/dl and platelet count, 77,000/mm 3 ) and marked resolution of subcutaneous venous engorgement.
DISCUSSION
Two underlying causes lead to a manifestation of BCS.
One is hepatic vein thrombosis, which is often associated with various coagulation defects and disorders. 6, 7 The other is membranous obstruction of hepatic veins or the IVC. 6 This latter cause is more common in Eastern countries and may be congenital in origin. BCS is regarded as a very rare disease entity in Korea.
Restoring hepatic venous outflow is the primary objective when treating BCS. Endovascular treatment is the main therapeutic choice with advances in interventional technology. 4, 8 A transjugular intrahepatic portosystemic shunt (TIPS) is currently the most common intervention (65-100%) at 1 year and 77% (53-100%) at 5 years.
11,12
The common complications of endovascular treatment for BCS include hepatic encephalopathy, bleeding into the abdominal cavity or biliary tract bleeding, and hepatic artery injury, among others. The reported overall incidence of complications is ＜3%, and mortality rate is about 1%. 13 The incidences of restenosis after balloon expansion and stenting of hepatic veins are 10-20% and 10%, In conclusion, endovascular stenting appears to be an effective treatment to alleviate portal pressure and prevent BCS-associated complications; thus, endovascular stenting should be considered before marked stenosis or complete occlusion occurs in patients with BCS.
